About Lundbeck
Lundbeck is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Brain disorders
According to the World Health Organization (WHO) more than 700 million cases of brain disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of patients as well as of their relatives.
As these diseases also involve major socio-economic costs, it is imperative for society as a whole that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised treatment options, but there is still a great unmet need for new and innovative therapeutics.
Research and development
Lundbeck is one of Denmark’s most research-intensive enterprises. We employ approximately 1,200 highly-trained specialists in our research and development units. Each year, Lundbeck ploughs back around 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from brain disorders.
Products
Lundbeck markets a number of different pharmaceuticals for the treatment of brain disorders. The most recently launched compounds include: Cipralex/Lexapro® (depression), Ebixa® (Alzheimer’s disease), Azilect® (Parkinson’s disease), Xenazine® (chorea associated with Huntington's disease), Sabril® (epilepsy), Sycrest® (bipolar disorder) and OnfiTM (Lennox-Gastaut syndrome).
Key figures
Lundbeck employs 6.000 people worldwide, 2.000 of whom are based in Denmark. We have employees in 57 countries, and our products are registered in more than 100 countries. We have production facilities in Italy, France and Denmark and research centres in Denmark, China and the United States. Lundbeck generated revenue of approximately DKK 16 billion in 2011.
Management
Lundbeck’s overall management consists of our Executive Management (four members) headed by Ulf Wiinberg, President and CEO.
Market data
In 2011, 50% of our revenue derived from Europe, 26% from the USA and 22% from the International Markets region.
History
Lundbeck was founded by Hans Lundbeck as a trading company in 1915. Since then the company has evolved and grown dramatically. Today we are among the biggest Danish companies.
Ownership
In 1999, Lundbeck’s shares were listed on the Copenhagen Stock Exchange. The Lundbeck Foundation, which distributes more than DKK 300 million in grants for various types of research each year, owns about 70% of the shares in Lundbeck, while the remaining 30% are traded on the stock exchange.
